ReviewClinical endocrinology2014
Defending plasma T3 is a biological priority.
Review in Clinical endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- LT4/LT3 Combination Therapy vs. Monotherapy with LT4 for Persistent Symptoms of Hypothyroidism: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Amiodarone and thyroid physiology, pathophysiology, diagnosis and management.Trends in cardiovascular medicine · 2019Pooled it
- Trial
- Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study.Archives of endocrinology and metabolismTrial
- Stressful exposure from the 2004 Indian Ocean Tsunami drives long-term changes in thyroid hormone physiology.bioRxiv : the preprint server for biology · 2026Article
- Osteoprotective Effects of Melatonin on Bone Loss Associated with Dopaminergic Neuron Degeneration in a Rat Model of Parkinson Disease.Calcified tissue international · 2025Article
- FT3 and FT3/FT4 ratio are decreased and not compensated by levothyroxine treatment in TKI-treated thyroid cancer patients.Endocrine-related cancer · 2025Article
- Article
- Structural insights into thyroid hormone transporter MCT8.Nature communications · 2025Article
- Usefulness of SPINA model in evaluation of the thyroid function in euthyroid pediatric patients children with subclinical hypothyroidism.Frontiers in endocrinology · 2025Article
- Persistent symptoms in euthyroid Hashimoto's thyroiditis: current hypotheses and emerging management strategies.Frontiers in endocrinology · 2025Review
- Metabolic Consequences of Thyroidectomy and Patient-Centered Management.Journal of clinical medicine · 2024Review
- Validation of a triiodothyronine (T3) ELISA for mouse fecal samples.Physiological reports · 2024Article
- Thyroid Hormone Homeostasis in Levothyroxine-treated Patients: Findings From ELSA-Brasil.The Journal of clinical endocrinology and metabolism · 2024Article
- Risk Factors of Age-Related Macular Degeneration in a Population-Based Study: Results from SHIP-TREND-1 (Study of Health in Pomerania-TREND-1).Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Longevity, demographic characteristics, and socio-economic status are linked to triiodothyronine levels in the general population.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Correlation Between Thyroid Hormone and Controlled Attenuation Parameters: A Cross-Sectional Population-Based Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Epidemiology, Types, Causes, Clinical Presentation, Diagnosis, and Treatment of Hypothyroidism.Cureus · 2023Review
- Levothyroxine: Conventional and Novel Drug Delivery Formulations.Endocrine reviews · 2023Review
- Switching from Natural Desiccated Thyroid to a Liquid Formulation of Levothyroxine for Hypothyroidism.Case reports in endocrinology · 2023Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Triiodothyronine (T3), the active form of thyroid hormone is produced predominantly outside the thyroid parenchyma secondary to peripheral tissue deiodination of thyroxine (T4), with <20% being secreted directly from the thyroid. In healthy individuals, plasma T3 is regulated by the negative feedback loop of the hypothalamus-pituitary-thyroid axis and by homoeostatic changes in deiodinase expression. Therefore, with the exception of a minimal circadian rhythmicity, serum T3 levels are stable over long periods of time. Studies in rodents indicate that different levels of genetic disruption of the feedback mechanism and deiodinase system are met with increase in serum T4 and thyroid-stimulating hormone (TSH) levels, while serum T3 levels remain stable. These findings have focused attention on serum T3 levels in patients with thyroid disease, with important clinical implications affecting therapeutic goals and choice of therapy for patients with hypothyroidism. Although monotherapy with levothyroxine is the standard of care for hypothyroidism, not all patients normalize serum T3 levels with many advocating for combination therapy with levothyroxine and liothyronine. The latter could be relevant for a significant number of patients that remain symptomatic on monotherapy with levothyroxine, despite normalization of serum TSH levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.